Context
The success of CAR T-cells is now indisputable for B-cell malignancies and has merited FDA and EMA approval in 2018.
A new therapeutic opportunity for T-cell acute lymphoblastic leukemia patients
The carxall project aims to develop a universal treatment for multi-treated patients with advanced disease
The Problem
Strategies targeting T-cell malignancies using CARTs remain challenging because of the shared expresion of target antigens between normal and malignant T-cells.
Our Solution
In carxall project we develop a next generation, allogeneic, off-the shelf CAR T cell products for R/R T-ALL patients.